Genmab A (GMAB) Operating Income (2018 - 2026)
Genmab A (GMAB) posted Operating Income of $180.0 million for Q1 2026, down 82.13% on a QoQ basis from $1.0 billion in Q3 2025, and down 4.26% year-over-year from $188.0 million in Q1 2025.
Genmab A (GMAB) Operating Income (2018 - 2026) Analysis & Trends
Genmab A's Operating Income history runs 6 years deep, the most recent figure standing at $180.0 million for Q1 2026.
- Quarterly Operating Income fell 4.26% year-over-year to $180.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 45.9% YoY) and the FY2025 annual result came in at $1.1 billion, up 9.57% from the prior year.
- Operating Income was $180.0 million for Q1 2026 at Genmab A, down from $1.0 billion in the prior quarter.
- Across five years, Operating Income topped out at $1.0 billion in Q3 2025 and bottomed at $116.0 million in Q1 2024.
- A 3-year average of $436.1 million and a median of $352.0 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2025 — Operating Income surged 62.07% — and 2026, when it retreated 4.26%.
- Genmab A's Operating Income stood at $662.0 million in 2024, then jumped by 52.11% to $1.0 billion in 2025, then tumbled by 82.13% to $180.0 million in 2026.
- Business Quant data shows GMAB's Operating Income at $180.0 million in Q1 2026, $1.0 billion in Q3 2025, and $548.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 180.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 180.00 Mn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 548.00 Mn |
| Mar 31, 2025 | 188.00 Mn |
| Sep 30, 2024 | 662.00 Mn |
| Jun 30, 2024 | 352.00 Mn |
| Mar 31, 2024 | 116.00 Mn |
| Sep 30, 2020 | 1,715,910.00 Bn |
| Dec 31, 2019 | 1,721.78 |
| Sep 30, 2019 | 689.10 Mn |
| Dec 31, 2018 | 997.01 Mn |